Form 4: Contineum Therapeutics Director Sarah Boyce Granted Stock Options Under Equity Plan

Contineum Therapeutics, Inc. Director Sarah Boyce was granted 14,750 stock options with an exercise price of $4.01 per share, as part of the company's non-employee director compensation program.

Summary

• Sarah Boyce, a Director at Contineum Therapeutics, Inc. (CTNM), was granted 14,750 stock options.
• The options have an exercise price of $4.01 per share.
• The grant date for these options is June 26, 2025.
• These options were granted under the Issuer's 2024 Equity Incentive Plan and the Non-Employee Director Compensation Program.
• The options will vest in full on the earlier of June 26, 2026 (one-year anniversary of the grant date) or the next regular annual meeting of stockholders, subject to continuous service.
• The options expire on June 25, 2035.
• Following this transaction, Sarah Boyce beneficially owns 14,750 derivative securities directly.

Sentiment

Score: 7

Explanation: The filing reports a routine, pre-scheduled grant of stock options to a director as part of a compensation program. This is a neutral event with a slight positive tilt as it aligns director interests with shareholders, but it does not indicate any new strategic developments or financial performance.

Positives

• The grant of stock options aligns the interests of Director Sarah Boyce with those of shareholders, as the options gain value if the company's stock price increases.
• The transaction reflects the company's established Non-Employee Director Compensation Program, indicating a structured approach to executive incentives.

Future Outlook

The granted stock options are set to vest in full on the earlier of June 26, 2026, or the next regular annual meeting of stockholders, contingent on the director's continuous service. The options have an expiration date of June 25, 2035.

Industry Context

Granting stock options to non-employee directors is a common practice across various industries, including biotechnology and pharmaceuticals, to attract and retain qualified board members and align their interests with long-term shareholder value. This filing indicates Contineum Therapeutics follows standard corporate governance practices for director compensation.

Comparison to Industry Standards

• The grant of stock options to a non-employee director is a standard form of compensation in the biotechnology and pharmaceutical sectors, comparable to practices at companies like Moderna, BioNTech, or Regeneron, which frequently use equity-based incentives to compensate their board members and align their interests with company performance.
• While specific grant sizes vary based on company size, stage, and individual director roles, the mechanism itself is widely adopted.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors. This is a standard and disclosed form of related party compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• Vesting of the 14,750 stock options on the earlier of June 26, 2026, or the next regular annual meeting of stockholders.
• Potential exercise of options by Sarah Boyce before the expiration date of June 25, 2035.

Key Dates

Keywords

Contineum Therapeutics, CTNM, SEC Form 4, insider transaction, stock option grant, director compensation, equity incentive plan, Sarah Boyce, beneficial ownership